

Table S1. Generic and brand names of immune checkpoint inhibitors

Type of ICIs	Generic names	Brand names
Anti-PD 1 mAbs	Nivolumab	Opdivo
	Pembrolizumab	Keytruda
	Camrelizumab	
Anti-PD L1 mAbs	Atezolizumab	Tecentriq
	Avelumab	Bavencio
	Durvalumab	Imfinzi
Anti CTLA-4 mAbs	Ipilimumab	Yervoy
	Tremelimumab	Imjudo

Table S2. Two-by-two contingency table for disproportionality analysis

AE Cases	Target Adverse Event (AE)	All Other AEs	Total
Target drugs	a	b	a + b
Other drugs	c	d	c + d
Total	a + c	b + d	N = a + b + c + d

a: the number of records of target drug-AEs; b: the number of records of target drug-Not AEs; c: the number of records of other drugs-AEs; d: the number of records of other drug-Not AEs.

Table S3. The calculation formulas of ROR

Items	Calculation formulas
ROR	$ROR = \frac{(a/c)}{(b/d)}$
SE(lnROR)	$SE (\ln ROR) = \sqrt{\left(\frac{1}{a} + \frac{1}{b} + \frac{1}{c} + \frac{1}{d}\right)}$
95% CI	$95\%CI = e^{\ln(ROR) \pm 1.96 \sqrt{\left(\frac{1}{a} + \frac{1}{b} + \frac{1}{c} + \frac{1}{d}\right)}}$

Table S4. The search strategy and terms in descriptive study

Items	Steps	Search strategy and terms
Drug 1	#1	(PD-L1 Inhibitors[Title/Abstract]) OR (Programmed Death-Ligand 1 Inhibitors[Title/Abstract]) OR (Atezolizumab[Title/Abstract]) OR (Avelumab[Title/Abstract]) OR (Durvalumab[Title/Abstract])
Drug 2	#2	(PD-1 Inhibitors[Title/Abstract]) OR (Programmed Cell Death Protein 1 Inhibitor[Title/Abstract]) OR (Nivolumab[Title/Abstract]) OR (Pembrolizumab[Title/Abstract]) OR (Camrelizumab[Title/Abstract]) OR (Sintilimab[Title/Abstract]) OR (Toripalimab[Title/Abstract]) OR (Tislelizumab[Title/Abstract]) OR (Cemiplimab[Title/Abstract])
Hypophysitis	#3	(Isolated Adrenocorticotrophic Hormone Deficiency[Title/Abstract]) OR ("Hypophysitis"[Mesh]) OR (Immune-mediated hypophysitis[Title/Abstract]) OR (Hypophysitis[Title/Abstract]) OR (Secondary adrenocortical insufficiency[Title/Abstract]) OR (Secondary hypogonadism[Title/Abstract]) OR (Secondary hypothyroidism[Title/Abstract])
Search strategy	#1 OR #2 AND #3(to March 30, 2023)	